AVAXIM® Junior is indicated for active immunisation against infection caused by hepatitis A virus (HAV) in children aged 1 - 15 years.1
Before you prescribe this vaccine please refer to the Prescribing Information and SmPC link. The use of Avaxim Junior should be based on official recommendations.
Summary
Fast
- AVAXIM Junior provides rapid seroprotection against hepatitis A as early as two weeks from the first dose.1
- 14 days after the first dose of vaccination more than 94% of immunocompetent individuals are protected.*2
Flexible
- AVAXIM Junior is interchangeable with other paediatric inactivated hepatitis A vaccines as a booster with flexible booster timing.1
- The booster dose can be given between 6 months to 10 years after the first.1
Effective
- AVAXIM Junior offers long-lasting protection against Hepatits A, up to 10 years after initial immunisation.†1,3
*Seroconversion defined as anti-HAV antibody titres rising from <20 mlU/ml (seronegative) to ≥20 mIU/ml. Monocentric, open trial evaluating Avaxim in children aged 18 months – 3 years (n=37), 4 – 8 years (n=53) and 9-15 years (n=83). Two weeks after the first dose, seroconversion was achieved by 94.6% of initially HAV-seronegative subjects aged 18 months – 3 years, 94.3% of subjects aged 4-8 years and 96.4% of subjects aged 9-15 years.2
†Open non-controlled trial of Avaxim Pediatric vaccine in 537 healthy children aged 12 months to 15 years enrolled between December 1996 and January 1997. 54 children aged 12 to 60 months were invited for serum anti-HAV measurements at 10 years post first vaccine dose. In children who were seronegative at enrolment, 47/48 were seroprotected at 10 years. 6/6 children who were seropositive at enrolment were seroprotected at 10 years.3
AVAXIM Junior is shown to be generally well tolerated in young children.
Based on data from a pooled analysis, most undesirable effects following administration of AVAXIM Junior were limited to the first few days following immunisation with spontaneous recovery.*1
The most common adverse reactions (≥10%) were injection site pain, malaise, headache and abnormal crying.1
For the full list of adverse events please refer to the AVAXIM Junior summary of product characteristics.
*Pooled analysis integrated data from 5458 children aged from 12 months to 15 years of age who received at least one injection of Avaxim Junior during clinical trials.1
.
Vaccines Masterclass Series
Enhance your travel health expertise and earn valuable CPD points.
Vaccines Masterclass Series
Enhance your travel health expertise and earn valuable CPD points.
References
- Avaxim Junior Summary of Product Characteristics
- Dagan R, et al. Vaccine. 1999;17(15-16):1919-25
- López EL, et al. Pediatr Infect Dis J. 2010;29(6):568-70
MAT-XU-2301296 (v5.0) Date of preparation: May 2025